[go: up one dir, main page]

WO2006069000A3 - Klf2 utilise comme mediateur de l'activite des statines - Google Patents

Klf2 utilise comme mediateur de l'activite des statines Download PDF

Info

Publication number
WO2006069000A3
WO2006069000A3 PCT/US2005/045946 US2005045946W WO2006069000A3 WO 2006069000 A3 WO2006069000 A3 WO 2006069000A3 US 2005045946 W US2005045946 W US 2005045946W WO 2006069000 A3 WO2006069000 A3 WO 2006069000A3
Authority
WO
WIPO (PCT)
Prior art keywords
klf2
activity
mediator
compounds
identifying
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/045946
Other languages
English (en)
Other versions
WO2006069000A2 (fr
Inventor
Mukesh K Jain
Sucharita Senbanerjee
Pallab Banerjee
Zhiyong Lin
Gillermo Garcia-Cardena
Michael A Gimbrone Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Publication of WO2006069000A2 publication Critical patent/WO2006069000A2/fr
Anticipated expiration legal-status Critical
Publication of WO2006069000A3 publication Critical patent/WO2006069000A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5064—Endothelial cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des méthodes d'identification de composés imitant ou inhibant l'effet thérapeutique des statines. Les composés de l'invention sont identifiés par des dosages du facteur de transcription KLF2. L'invention concerne également des méthodes de création ou d'identification de cellules endothéliales présentant une faible activité de KLF2, lesquelles cellules sont résistantes au traitement par les statines. Elle concerne des méthodes permettant d'augmenter l'activité de KLF2 par transfection de cellules avec des vecteurs d'expression.
PCT/US2005/045946 2004-12-21 2005-12-20 Klf2 utilise comme mediateur de l'activite des statines Ceased WO2006069000A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US63766404P 2004-12-21 2004-12-21
US60/637,664 2004-12-21
US65738205P 2005-03-02 2005-03-02
US60/657,382 2005-03-02

Publications (2)

Publication Number Publication Date
WO2006069000A2 WO2006069000A2 (fr) 2006-06-29
WO2006069000A3 true WO2006069000A3 (fr) 2007-08-09

Family

ID=36602241

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/045946 Ceased WO2006069000A2 (fr) 2004-12-21 2005-12-20 Klf2 utilise comme mediateur de l'activite des statines

Country Status (1)

Country Link
WO (1) WO2006069000A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1614429A4 (fr) * 2003-04-17 2007-05-02 Kowa Co Promoteur de l'expression du gene lklf/klf2
WO2008132458A1 (fr) * 2007-04-30 2008-11-06 Inion Limited Compositions utiles dans la modulation de réponses immunitaires et le traitement ou la prévention de réponses inflammatoires et procédés apparentés

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004039956A2 (fr) * 2002-10-29 2004-05-13 Genentech, Inc. Compositions et methodes de traitement de maladies liees au systeme immunitaire

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004039956A2 (fr) * 2002-10-29 2004-05-13 Genentech, Inc. Compositions et methodes de traitement de maladies liees au systeme immunitaire

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DEKKER ET AL.: "Prolonged fluid shear stress induces a distinct set of endothelial cell genes most specifically lung Kruppel-factor (KLF2)", BLOOD, vol. 100, no. 5, September 2002 (2002-09-01), pages 1689 - 1698, XP002425163, DOI: doi:10.1182/blood-2002-01-0046 *
WANI ET AL.: "cDNA isolation, genomic structure, regulation, and chromosomal localization of human lung Kruppel-like factor", GENOMICS, vol. 60, 1999, pages 78 - 86, XP004444838, DOI: doi:10.1006/geno.1999.5888 *

Also Published As

Publication number Publication date
WO2006069000A2 (fr) 2006-06-29

Similar Documents

Publication Publication Date Title
DE602006012539D1 (de) Herstellung von peraciden unter verwendung eines enzyms mit perhydrolyse-aktivität
WO2006031994A3 (fr) Domaines fc monomeres des immunoglobulines
WO2006092213A8 (fr) Pyrazolylcarboxanilides
ATE546044T1 (de) Verwendung von alkylcarbonsäureamiden als penetrationsförderer
WO2006105448A3 (fr) Proliferation de cellules exprimant la muc1
WO2006015124A3 (fr) Modulateurs heterocycliques a cycles fusionnes pour les kinases
WO2010148223A3 (fr) Anticorps anti-vegf et leurs utilisations
TNSN07027A1 (en) Pyrrolo-pyridine kinase modulators
WO2007041610A3 (fr) Genes et proteines associes a l'angiogenese et leurs utilisations
GB2489187A (en) Compositions,methods and related uses for cleaving modified DNA
EP2374884A3 (fr) Molécules d'ARNmi isolées des cellules souches mésenchymateuses humaines
CY1112877T1 (el) Μεταλλαγματα αυξητικου παραγoντα υψηλης δραστικοτητας
WO2007140390A3 (fr) Procédé de modulation de la pousse des cheveux
WO2009083790A8 (fr) Régulation positive induisant l'apoptose dans des expériences de modulation d'expression
WO2006069000A3 (fr) Klf2 utilise comme mediateur de l'activite des statines
ATE488591T1 (de) Neuer l-lysin-induzierbarer promotor
DE502006005179D1 (de) Verfahren zur enantioselektiven enzymatischen reduktion von ketoverbindungen
DE502005003027D1 (de) Elektrolysezelle zur herstellung von alkalimetall
ATE542796T1 (de) N-sulfonylcarboximidamidverbindungen als apoptosepromotoren
WO2006132739A3 (fr) Nouveaux composes chimiques
TW200639195A (en) Curable composition and its uses
WO2005070042A8 (fr) Nouveaux composes chimiques
ATE519364T1 (de) Kryokonservierung von hepatocyten
WO2005079378A3 (fr) Techniques synthetiques et intermediaires pour des lactones de polyhydroxy dienyle et leurs analogues
DK1856249T3 (da) Vækstfaktormutanter med forbedret biologisk aktivitet

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05854623

Country of ref document: EP

Kind code of ref document: A2